U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1925
    -0.0054 (-0.45%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3827
    -0.0067 (-0.48%)
     
  • USD/JPY

    108.2450
    +0.2690 (+0.25%)
     
  • BTC-USD

    48,862.30
    +660.95 (+1.37%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

GW Pharmaceuticals PLC (GWPH) Gains As Market Dips: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
  • Oops!
    Something went wrong.
    Please try again later.

GW Pharmaceuticals PLC (GWPH) closed at $162.45 in the latest trading session, marking a +0.88% move from the prior day. This change outpaced the S&P 500's 0.04% loss on the day. Elsewhere, the Dow lost 0.51%, while the tech-heavy Nasdaq added 0.21%.

Heading into today, shares of the company had lost 1.64% over the past month, outpacing the Medical sector's loss of 5.37% and lagging the S&P 500's gain of 4.65% in that time.

GWPH will be looking to display strength as it nears its next earnings release, which is expected to be May 6, 2019. The company is expected to report EPS of -$2.48, up 20.51% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $23.21 million, up 592.69% from the year-ago period.

Investors might also notice recent changes to analyst estimates for GWPH. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 7.06% higher within the past month. GWPH is holding a Zacks Rank of #3 (Hold) right now.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 145, putting it in the bottom 44% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GW Pharmaceuticals PLC (GWPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.